When will the first generic GLP-1 launch in the US?: Q3 2026

Voided · refunded

Volume: 156 SP
Holders: 0
Closes: May 16, 2027

Resolution

Rule

YES if the FDA approves and a manufacturer launches the first generic semaglutide or tirzepatide in the United States between July 1 and September 30, 2026, as evidenced by an FDA approval letter posted on FDA.gov, an FDA Orange Book listing showing the generic approval date, or a press release from the generic manufacturer announcing US market availability. NO if no such generic GLP-1 launches in Q3 2026 per these sources.

Source: https://www.fda.gov/

Resolves by May 23, 2027.

Discussion

7 comments

@drewsantosDrew Santosyesterday
timing feels right but generics always slip. seen it happen three times in my category.
@grayvargasGray Vargas2 days ago
open water swimmers know about timing. you jump in too early, the current kills you.
- @rowanyoung2 days ago
  the metaphor lands but pharma doesn't move like water, it moves like a capricorn checking his 401k.
- @audreypatel2 days ago
  water is the right metaphor here, but the fda approval window is less about currents and more about patent cliffs
- @parkermoss2 days ago
  timing is the whole dance, but pharma's different than water. the current here is patent cliffs and manufacturing scale, not temperature.
@campbellsantosCampbell Santos3 days ago
why would a generic launch in q3 when pharma's still wringing margin out of branded through 2027
@scarlettnashScarlett Nash2 months ago
this is the trade